BioSpace News Archive

Drug Development

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed.

July 12, 2022
·
1 min read
Demand For PCR Reagents Is Projected To Increase At A Healthy CAGR Of 6.4% Over 2022-2032, States Fact.MR

Fact.MR, a market research and competitive intelligence provider: The global PCR reagents market is estimated at US$ 1.25 billion in 2022.

July 12, 2022
·
8 min read
Biotech Bay

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

Oncology Pharma, Inc. is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug delivery system.

July 12, 2022
·
4 min read
Drug Development

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

scPharmaceuticals Inc. today announced positive results from the AT HOME-HF Pilot study, a Phase 2, multicenter, randomized study that compared scPharmaceuticals’ investigational product, FUROSCIX.

July 12, 2022
·
8 min read
Business

Agile Therapeutics Updates Second Quarter 2022 Guidance

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that it has updated its second quarter 2022 Twirla demand (total cycles) and operating expense (OPEX) guidance that was initially provided on May 24, 2022.

July 12, 2022
·
5 min read
Business

Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to announce the appointment of Philip Sutton, Ph.D., as Vice President of Translational Sciences.

July 12, 2022
·
3 min read
Business

Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary unaudited product revenues for the six and three months ended June 30, 2022.

July 12, 2022
·
4 min read
Drug Development

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial.

July 12, 2022
·
5 min read
Business

Providence Therapeutics Signs Licensing Agreement with SickKids for Immunotargeting Technology

Providence Therapeutics, Canada’s premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children (SickKids) of Toronto, ON , for an immunotargeting technology platform.

July 12, 2022
·
4 min read
Business

InMode Expects Record Second Quarter 2022 Financial Results, Revenue Between $113.0-$113.3M, Increasing Full Year 2022 Revenue Guidance to $425-$435M

InMode Ltd. (Nasdaq: INMD ) , a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2022 before the Nasdaq market opens on Thursday, July 28, 2022.

July 12, 2022
·
5 min read